Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study

OBJECTIVES: The aim of this work is to verify the non-inferior efficacy and safety of CMAB008 compared with innovator infliximab in rheumatoid arthritis patients combined with methotrexate. METHODS: We conducted a randomized, double-blinded, parallel, positive control design, multicenter study, with...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Hua, Liu, Shengyun, Xu, Jian, Chai, Kexia, He, Dongyi, Fang, Yongfei, Xie, Qibing, Liu, Huaxiang, Liu, Ying, Hua, Bingzhu, Hu, Jiankang, Zhang, Zhiyi, Zhou, Mingxuan, Zhao, Dongbao, Li, Yan, Jiang, Zhenyu, Wang, Meimei, Li, Jingyang, Zhang, Zhuoli, Li, Xiaomei, Li, Yang, Sun, Erwei, Bi, Liqi, Wei, Wei, Tie, Ning, He, Lan, Huang, Xiangyang, Zhang, Yan, Huang, Qingchun, Wang, Xiaofei, Liu, Xiangyuan, Li, Jing, Su, Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140208/
https://www.ncbi.nlm.nih.gov/pubmed/36964872
http://dx.doi.org/10.1007/s40744-023-00544-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140208/
https://www.ncbi.nlm.nih.gov/pubmed/36964872
http://dx.doi.org/10.1007/s40744-023-00544-2

Ejemplares similares